ACT1

ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research[1].

Product Specifications

CAS Number

[895547-36-1]

UNSPSC

12352209

Target

Gap Junction Protein

Related Pathways

Cytoskeleton

Field of Research

Cancer

Smiles

O=C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N9[C@@H](CCC9)C(N[C@@H](CCCNC(N)=N)C(N%10[C@@H](CCC%10)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

Molecular Formula

C150H238N48O34

Molecular Weight

3257.80

References & Citations

[1]Grek CL, et al. Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 3;15:296.